According to the K–M curve results, AML patients belonging to the RAS‐A subgroup exhibited a more favorable prognosis (overall survival [OS]) than those belonging to the RAS‐B subgroup (p = 0.02, Figure 2E). This evidence concerns the gene RASA1 and acute myeloid leukemia.